title: Influence of pretreatment with H2 receptor antagonists on the cure rates of Helicobacter pylori eradication.
abstract: BACKGROUND
  Pretreatment with a proton pump inhibitor (PPI) reportedly decreases the efficacy of Helicobacter pylori (H. pylori) eradication, however, the effect of pretreatment with an H2 receptor antagonist (H2RA) on H. pylori eradication has not yet been studied. We compared the efficacy of eradication regimen (lansoprazole/amoxicillin/clarithromycin) in patients with H. pylori infection with or without H2RA pretreatment.
  
  
  METHODS
  In this retrospective study conducted at three centers, 310 patients with H. pylori infection were treated. The diagnosis of H. pylori infection was made using the rapid urease test, bacterial cultures and histological examination of endoscopic biopsy specimens. The patients were assigned to receive an eradication regimen first or following pretreatment with H2RA. Eradication was assessed using the 13C-urea breath test more than 4 weeks after the completion of therapy.
  
  
  RESULTS
  Overall, H. pylori was eradicated in 79.7% of the cases: the eradication rate was 81.6% in the pretreatment group, and 77.6% in the eradication first group (p=0.3799, chi-square test). No significant difference in the eradication rate was observed between the two groups.
  
  
  CONCLUSIONS
  Pretreatment with H2RA had no significant influence on the efficacy of H. pylori eradication therapy.
authors.affiliation: Gastroenterology Division, Yokohama City University Hospital, Yokohama, Japan.
authors.forename: Chikako
authors.initials: C
authors.lastname: Tokoro
authors.forename: Masahiko
authors.initials: M
authors.lastname: Inamori
authors.forename: Tomoko
authors.initials: T
authors.lastname: Koide
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Sekino
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iida
authors.forename: Yasunari
authors.initials: Y
authors.lastname: Sakamoto
authors.forename: Hiroki
authors.initials: H
authors.lastname: Endo
authors.forename: Kunihiro
authors.initials: K
authors.lastname: Hosono
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Masato
authors.initials: M
authors.lastname: Yoneda
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Yasuzaki
authors.forename: Masami
authors.initials: M
authors.lastname: Ogawa
authors.forename: Yasunobu
authors.initials: Y
authors.lastname: Abe
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kubota
authors.forename: Satoru
authors.initials: S
authors.lastname: Saito
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawana
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakajima
authors.forename: Shin
authors.initials: S
authors.lastname: Maeda
authors.forename: Reikei
authors.initials: R
authors.lastname: Matsuda
authors.forename: Daisuke
authors.initials: D
authors.lastname: Takahashi
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D016480:Helicobacter pylori / Q000187:drug effects*; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D017211:Treatment Failure; D055815:Young Adult
chemical_list: D006635:Histamine H2 Antagonists